Literature DB >> 2940960

Dopamine D2 receptor density remains constant in treated Parkinson's disease.

M Guttman, P Seeman, G P Reynolds, P Riederer, K Jellinger, W W Tourtellotte.   

Abstract

D2 dopamine receptor densities were measured in postmortem samples of the caudate nucleus and putamen from 36 parkinsonian patients. The relationship between the age of the patient, duration of the disease, and duration of L-dopa therapy versus density of brain D2 dopamine receptors was examined using [3H]spiperone. Receptor density in parkinsonian tissues was constant over the age range of 56 to 90 years, as was the case for control tissues. Density did not change with duration of disease up to 24 years. Treatment with L-dopa did not cause progressive reduction in receptor density. The diminished clinical response in the final stages of Parkinson's disease is not due to receptor dropout, and must depend on other factors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940960     DOI: 10.1002/ana.410190510

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  17 in total

Review 1.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

2.  Increased uptake sites for serotonin and dopamine with decreased S2 serotonin receptors in microencephalic rat brain.

Authors:  M Watanabe; M Kinuya; G Mamiya; T Tatsunuma; M Nagayoshi; T Matsutani; Y Tsukada
Journal:  Neurochem Res       Date:  1990-10       Impact factor: 3.996

3.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

5.  L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.

Authors:  S Ferre; M Casas; A Cobos; C Garcia; F Jane; J M Grau
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

7.  Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.

Authors:  M Rodriguez; G Lera; J Vaamonde; M R Luquin; J A Obeso
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-05       Impact factor: 10.154

8.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study.

Authors:  T Brücke; E Sofic; W Killian; A Rett; P Riederer
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

10.  Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.

Authors:  L J Porrino; R S Burns; A M Crane; E Palombo; I J Kopin; L Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.